Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)
Background The p.Arg14del (c.40_42delAGA) phospholamban (PLN) pathogenic variant is a founder mutation that causes dilated cardiomyopathy (DCM) and arrhythmogenic cardiomyopathy (ACM). Carriers are at increased risk of malignant ventricular arrhythmias and heart failure, which has been ascribed to c...
Gespeichert in:
| Veröffentlicht in: | Netherlands heart journal 2022-02, Vol.30 (2), p.84-95 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 95 |
|---|---|
| container_issue | 2 |
| container_start_page | 84 |
| container_title | Netherlands heart journal |
| container_volume | 30 |
| creator | te Rijdt, W. P. Hoorntje, E. T. de Brouwer, R. Oomen, A. Amin, A. van der Heijden, J. F. Karper, J. C. Westenbrink, B. D. Silljé, H. H. W. te Riele, A. S. J. M. Wiesfeld, A. C. P. van Gelder, I. C. Willems, T. P. van der Zwaag, P. A. van Tintelen, J. P. Hillege, J. H. Tan, H. L. van Veldhuisen, D. J. Asselbergs, F. W. de Boer, R. A. Wilde, A. A. M. van den Berg, M. P. |
| description | Background
The p.Arg14del (c.40_42delAGA) phospholamban (PLN) pathogenic variant is a founder mutation that causes dilated cardiomyopathy (DCM) and arrhythmogenic cardiomyopathy (ACM). Carriers are at increased risk of malignant ventricular arrhythmias and heart failure, which has been ascribed to cardiac fibrosis. Importantly, cardiac fibrosis appears to be an early feature of the disease, occurring in many presymptomatic carriers before the onset of overt disease. As with most monogenic cardiomyopathies, no evidence-based treatment is available for presymptomatic carriers.
Aims
The PHOspholamban RElated CArdiomyopathy intervention STudy (iPHORECAST) is designed to demonstrate that pre-emptive treatment of presymptomatic PLN p.Arg14del carriers using eplerenone, a mineralocorticoid receptor antagonist with established antifibrotic effects, can reduce disease progression and postpone the onset of overt disease.
Methods
iPHORECAST has a multicentre, prospective, randomised, open-label, blinded endpoint (PROBE) design. Presymptomatic PLN p.Arg14del carriers are randomised to receive either 50 mg eplerenone once daily or no treatment. The primary endpoint of the study is a multiparametric assessment of disease progression including cardiac magnetic resonance parameters (left and right ventricular volumes, systolic function and fibrosis), electrocardiographic parameters (QRS voltage, ventricular ectopy), signs and/or symptoms related to DCM and ACM, and cardiovascular death. The follow-up duration is set at 3 years.
Baseline results
A total of 84 presymptomatic PLN p.Arg14del carriers (
n
= 42 per group) were included. By design, at baseline, all participants were in New York Heart Association (NHYA) class I and had a left ventricular ejection fraction > 45% and |
| doi_str_mv | 10.1007/s12471-021-01584-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8799798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2729534655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-4d67f87e49cc1e1cf883574594fb1273fd65ea2b29128a9ea537e10c7f85d9e13</originalsourceid><addsrcrecordid>eNp9kUtvGyEUhVHVqnm0f6CLCqmbZDEtMDDAppJluU2lSIkcd43wcMcmmgEXZiL53xfXafpYZHEF0v3O4XIPQu8o-UgJkZ8yZVzSirBSVCheiRfolCrZVA0T5GW5i0ZVQil1gs5yvidESEbla3RSc8pLNafILu3oY7A9YBscdpD9JuDY4XEL-PbqJu-2sbfD2ga8XPR2BIfns-R8HPZxZ8ftHvswQnqAcLDBd6vJ7fGFr4p0uZjP7laXb9CrzvYZ3j6e5-j7l8VqflVd33z9Np9dVy2XfKy4a2SnJHDdthRo2ylVC8mF5t2aMll3rhFg2ZppypTVYEUtgZK2iITTQOtz9Pnou5vWA7i2TJRsb3bJDzbtTbTe_NsJfms28cEoqbXUqhhcPBqk-GOCPJrB5xb63gaIUzZMlJ0JzmpS0A__ofdxSmWLhZJMi5o3QhSKHak2xZwTdE_DUGIOCZpjgqYkaH4laA6i939_40nyO7IC1Ecgl1bYQPrz9jO2PwGjiKZA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2729534655</pqid></control><display><type>article</type><title>Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Springer Nature OA/Free Journals</source><creator>te Rijdt, W. P. ; Hoorntje, E. T. ; de Brouwer, R. ; Oomen, A. ; Amin, A. ; van der Heijden, J. F. ; Karper, J. C. ; Westenbrink, B. D. ; Silljé, H. H. W. ; te Riele, A. S. J. M. ; Wiesfeld, A. C. P. ; van Gelder, I. C. ; Willems, T. P. ; van der Zwaag, P. A. ; van Tintelen, J. P. ; Hillege, J. H. ; Tan, H. L. ; van Veldhuisen, D. J. ; Asselbergs, F. W. ; de Boer, R. A. ; Wilde, A. A. M. ; van den Berg, M. P.</creator><creatorcontrib>te Rijdt, W. P. ; Hoorntje, E. T. ; de Brouwer, R. ; Oomen, A. ; Amin, A. ; van der Heijden, J. F. ; Karper, J. C. ; Westenbrink, B. D. ; Silljé, H. H. W. ; te Riele, A. S. J. M. ; Wiesfeld, A. C. P. ; van Gelder, I. C. ; Willems, T. P. ; van der Zwaag, P. A. ; van Tintelen, J. P. ; Hillege, J. H. ; Tan, H. L. ; van Veldhuisen, D. J. ; Asselbergs, F. W. ; de Boer, R. A. ; Wilde, A. A. M. ; van den Berg, M. P.</creatorcontrib><description>Background
The p.Arg14del (c.40_42delAGA) phospholamban (PLN) pathogenic variant is a founder mutation that causes dilated cardiomyopathy (DCM) and arrhythmogenic cardiomyopathy (ACM). Carriers are at increased risk of malignant ventricular arrhythmias and heart failure, which has been ascribed to cardiac fibrosis. Importantly, cardiac fibrosis appears to be an early feature of the disease, occurring in many presymptomatic carriers before the onset of overt disease. As with most monogenic cardiomyopathies, no evidence-based treatment is available for presymptomatic carriers.
Aims
The PHOspholamban RElated CArdiomyopathy intervention STudy (iPHORECAST) is designed to demonstrate that pre-emptive treatment of presymptomatic PLN p.Arg14del carriers using eplerenone, a mineralocorticoid receptor antagonist with established antifibrotic effects, can reduce disease progression and postpone the onset of overt disease.
Methods
iPHORECAST has a multicentre, prospective, randomised, open-label, blinded endpoint (PROBE) design. Presymptomatic PLN p.Arg14del carriers are randomised to receive either 50 mg eplerenone once daily or no treatment. The primary endpoint of the study is a multiparametric assessment of disease progression including cardiac magnetic resonance parameters (left and right ventricular volumes, systolic function and fibrosis), electrocardiographic parameters (QRS voltage, ventricular ectopy), signs and/or symptoms related to DCM and ACM, and cardiovascular death. The follow-up duration is set at 3 years.
Baseline results
A total of 84 presymptomatic PLN p.Arg14del carriers (
n
= 42 per group) were included. By design, at baseline, all participants were in New York Heart Association (NHYA) class I and had a left ventricular ejection fraction > 45% and < 2500 ventricular premature contractions during 24-hour Holter monitoring. There were no statistically significant differences between the two groups in any of the baseline characteristics. The study is currently well underway, with the last participants expected to finish in 2021.
Conclusion
iPHORECAST is a multicentre, prospective randomised controlled trial designed to address whether pre-emptive treatment of PLN p.Arg14del carriers with eplerenone can prevent or delay the onset of cardiomyopathy. iPHORECAST has been registered in the clinicaltrials.gov-register (number: NCT01857856).</description><identifier>ISSN: 1568-5888</identifier><identifier>EISSN: 1876-6250</identifier><identifier>DOI: 10.1007/s12471-021-01584-5</identifier><identifier>PMID: 34143416</identifier><language>eng</language><publisher>Houten: Bohn Stafleu van Loghum</publisher><subject>Cardiac arrhythmia ; Cardiology ; Cardiomyocytes ; Cardiomyopathy ; Drug dosages ; Ejection fraction ; Electrocardiography ; Ergometry ; Heart failure ; Hyperkalemia ; Medical Education ; Medical ethics ; Medicine ; Medicine & Public Health ; Original Article – Study Design Article ; Original – Study Design ; Outpatient care facilities ; Potassium ; Task forces</subject><ispartof>Netherlands heart journal, 2022-02, Vol.30 (2), p.84-95</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-4d67f87e49cc1e1cf883574594fb1273fd65ea2b29128a9ea537e10c7f85d9e13</citedby><cites>FETCH-LOGICAL-c474t-4d67f87e49cc1e1cf883574594fb1273fd65ea2b29128a9ea537e10c7f85d9e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799798/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799798/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34143416$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>te Rijdt, W. P.</creatorcontrib><creatorcontrib>Hoorntje, E. T.</creatorcontrib><creatorcontrib>de Brouwer, R.</creatorcontrib><creatorcontrib>Oomen, A.</creatorcontrib><creatorcontrib>Amin, A.</creatorcontrib><creatorcontrib>van der Heijden, J. F.</creatorcontrib><creatorcontrib>Karper, J. C.</creatorcontrib><creatorcontrib>Westenbrink, B. D.</creatorcontrib><creatorcontrib>Silljé, H. H. W.</creatorcontrib><creatorcontrib>te Riele, A. S. J. M.</creatorcontrib><creatorcontrib>Wiesfeld, A. C. P.</creatorcontrib><creatorcontrib>van Gelder, I. C.</creatorcontrib><creatorcontrib>Willems, T. P.</creatorcontrib><creatorcontrib>van der Zwaag, P. A.</creatorcontrib><creatorcontrib>van Tintelen, J. P.</creatorcontrib><creatorcontrib>Hillege, J. H.</creatorcontrib><creatorcontrib>Tan, H. L.</creatorcontrib><creatorcontrib>van Veldhuisen, D. J.</creatorcontrib><creatorcontrib>Asselbergs, F. W.</creatorcontrib><creatorcontrib>de Boer, R. A.</creatorcontrib><creatorcontrib>Wilde, A. A. M.</creatorcontrib><creatorcontrib>van den Berg, M. P.</creatorcontrib><title>Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)</title><title>Netherlands heart journal</title><addtitle>Neth Heart J</addtitle><addtitle>Neth Heart J</addtitle><description>Background
The p.Arg14del (c.40_42delAGA) phospholamban (PLN) pathogenic variant is a founder mutation that causes dilated cardiomyopathy (DCM) and arrhythmogenic cardiomyopathy (ACM). Carriers are at increased risk of malignant ventricular arrhythmias and heart failure, which has been ascribed to cardiac fibrosis. Importantly, cardiac fibrosis appears to be an early feature of the disease, occurring in many presymptomatic carriers before the onset of overt disease. As with most monogenic cardiomyopathies, no evidence-based treatment is available for presymptomatic carriers.
Aims
The PHOspholamban RElated CArdiomyopathy intervention STudy (iPHORECAST) is designed to demonstrate that pre-emptive treatment of presymptomatic PLN p.Arg14del carriers using eplerenone, a mineralocorticoid receptor antagonist with established antifibrotic effects, can reduce disease progression and postpone the onset of overt disease.
Methods
iPHORECAST has a multicentre, prospective, randomised, open-label, blinded endpoint (PROBE) design. Presymptomatic PLN p.Arg14del carriers are randomised to receive either 50 mg eplerenone once daily or no treatment. The primary endpoint of the study is a multiparametric assessment of disease progression including cardiac magnetic resonance parameters (left and right ventricular volumes, systolic function and fibrosis), electrocardiographic parameters (QRS voltage, ventricular ectopy), signs and/or symptoms related to DCM and ACM, and cardiovascular death. The follow-up duration is set at 3 years.
Baseline results
A total of 84 presymptomatic PLN p.Arg14del carriers (
n
= 42 per group) were included. By design, at baseline, all participants were in New York Heart Association (NHYA) class I and had a left ventricular ejection fraction > 45% and < 2500 ventricular premature contractions during 24-hour Holter monitoring. There were no statistically significant differences between the two groups in any of the baseline characteristics. The study is currently well underway, with the last participants expected to finish in 2021.
Conclusion
iPHORECAST is a multicentre, prospective randomised controlled trial designed to address whether pre-emptive treatment of PLN p.Arg14del carriers with eplerenone can prevent or delay the onset of cardiomyopathy. iPHORECAST has been registered in the clinicaltrials.gov-register (number: NCT01857856).</description><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Cardiomyocytes</subject><subject>Cardiomyopathy</subject><subject>Drug dosages</subject><subject>Ejection fraction</subject><subject>Electrocardiography</subject><subject>Ergometry</subject><subject>Heart failure</subject><subject>Hyperkalemia</subject><subject>Medical Education</subject><subject>Medical ethics</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article – Study Design Article</subject><subject>Original – Study Design</subject><subject>Outpatient care facilities</subject><subject>Potassium</subject><subject>Task forces</subject><issn>1568-5888</issn><issn>1876-6250</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtvGyEUhVHVqnm0f6CLCqmbZDEtMDDAppJluU2lSIkcd43wcMcmmgEXZiL53xfXafpYZHEF0v3O4XIPQu8o-UgJkZ8yZVzSirBSVCheiRfolCrZVA0T5GW5i0ZVQil1gs5yvidESEbla3RSc8pLNafILu3oY7A9YBscdpD9JuDY4XEL-PbqJu-2sbfD2ga8XPR2BIfns-R8HPZxZ8ftHvswQnqAcLDBd6vJ7fGFr4p0uZjP7laXb9CrzvYZ3j6e5-j7l8VqflVd33z9Np9dVy2XfKy4a2SnJHDdthRo2ylVC8mF5t2aMll3rhFg2ZppypTVYEUtgZK2iITTQOtz9Pnou5vWA7i2TJRsb3bJDzbtTbTe_NsJfms28cEoqbXUqhhcPBqk-GOCPJrB5xb63gaIUzZMlJ0JzmpS0A__ofdxSmWLhZJMi5o3QhSKHak2xZwTdE_DUGIOCZpjgqYkaH4laA6i939_40nyO7IC1Ecgl1bYQPrz9jO2PwGjiKZA</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>te Rijdt, W. P.</creator><creator>Hoorntje, E. T.</creator><creator>de Brouwer, R.</creator><creator>Oomen, A.</creator><creator>Amin, A.</creator><creator>van der Heijden, J. F.</creator><creator>Karper, J. C.</creator><creator>Westenbrink, B. D.</creator><creator>Silljé, H. H. W.</creator><creator>te Riele, A. S. J. M.</creator><creator>Wiesfeld, A. C. P.</creator><creator>van Gelder, I. C.</creator><creator>Willems, T. P.</creator><creator>van der Zwaag, P. A.</creator><creator>van Tintelen, J. P.</creator><creator>Hillege, J. H.</creator><creator>Tan, H. L.</creator><creator>van Veldhuisen, D. J.</creator><creator>Asselbergs, F. W.</creator><creator>de Boer, R. A.</creator><creator>Wilde, A. A. M.</creator><creator>van den Berg, M. P.</creator><general>Bohn Stafleu van Loghum</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220201</creationdate><title>Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)</title><author>te Rijdt, W. P. ; Hoorntje, E. T. ; de Brouwer, R. ; Oomen, A. ; Amin, A. ; van der Heijden, J. F. ; Karper, J. C. ; Westenbrink, B. D. ; Silljé, H. H. W. ; te Riele, A. S. J. M. ; Wiesfeld, A. C. P. ; van Gelder, I. C. ; Willems, T. P. ; van der Zwaag, P. A. ; van Tintelen, J. P. ; Hillege, J. H. ; Tan, H. L. ; van Veldhuisen, D. J. ; Asselbergs, F. W. ; de Boer, R. A. ; Wilde, A. A. M. ; van den Berg, M. P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-4d67f87e49cc1e1cf883574594fb1273fd65ea2b29128a9ea537e10c7f85d9e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Cardiomyocytes</topic><topic>Cardiomyopathy</topic><topic>Drug dosages</topic><topic>Ejection fraction</topic><topic>Electrocardiography</topic><topic>Ergometry</topic><topic>Heart failure</topic><topic>Hyperkalemia</topic><topic>Medical Education</topic><topic>Medical ethics</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article – Study Design Article</topic><topic>Original – Study Design</topic><topic>Outpatient care facilities</topic><topic>Potassium</topic><topic>Task forces</topic><toplevel>online_resources</toplevel><creatorcontrib>te Rijdt, W. P.</creatorcontrib><creatorcontrib>Hoorntje, E. T.</creatorcontrib><creatorcontrib>de Brouwer, R.</creatorcontrib><creatorcontrib>Oomen, A.</creatorcontrib><creatorcontrib>Amin, A.</creatorcontrib><creatorcontrib>van der Heijden, J. F.</creatorcontrib><creatorcontrib>Karper, J. C.</creatorcontrib><creatorcontrib>Westenbrink, B. D.</creatorcontrib><creatorcontrib>Silljé, H. H. W.</creatorcontrib><creatorcontrib>te Riele, A. S. J. M.</creatorcontrib><creatorcontrib>Wiesfeld, A. C. P.</creatorcontrib><creatorcontrib>van Gelder, I. C.</creatorcontrib><creatorcontrib>Willems, T. P.</creatorcontrib><creatorcontrib>van der Zwaag, P. A.</creatorcontrib><creatorcontrib>van Tintelen, J. P.</creatorcontrib><creatorcontrib>Hillege, J. H.</creatorcontrib><creatorcontrib>Tan, H. L.</creatorcontrib><creatorcontrib>van Veldhuisen, D. J.</creatorcontrib><creatorcontrib>Asselbergs, F. W.</creatorcontrib><creatorcontrib>de Boer, R. A.</creatorcontrib><creatorcontrib>Wilde, A. A. M.</creatorcontrib><creatorcontrib>van den Berg, M. P.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Netherlands heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>te Rijdt, W. P.</au><au>Hoorntje, E. T.</au><au>de Brouwer, R.</au><au>Oomen, A.</au><au>Amin, A.</au><au>van der Heijden, J. F.</au><au>Karper, J. C.</au><au>Westenbrink, B. D.</au><au>Silljé, H. H. W.</au><au>te Riele, A. S. J. M.</au><au>Wiesfeld, A. C. P.</au><au>van Gelder, I. C.</au><au>Willems, T. P.</au><au>van der Zwaag, P. A.</au><au>van Tintelen, J. P.</au><au>Hillege, J. H.</au><au>Tan, H. L.</au><au>van Veldhuisen, D. J.</au><au>Asselbergs, F. W.</au><au>de Boer, R. A.</au><au>Wilde, A. A. M.</au><au>van den Berg, M. P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)</atitle><jtitle>Netherlands heart journal</jtitle><stitle>Neth Heart J</stitle><addtitle>Neth Heart J</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>30</volume><issue>2</issue><spage>84</spage><epage>95</epage><pages>84-95</pages><issn>1568-5888</issn><eissn>1876-6250</eissn><abstract>Background
The p.Arg14del (c.40_42delAGA) phospholamban (PLN) pathogenic variant is a founder mutation that causes dilated cardiomyopathy (DCM) and arrhythmogenic cardiomyopathy (ACM). Carriers are at increased risk of malignant ventricular arrhythmias and heart failure, which has been ascribed to cardiac fibrosis. Importantly, cardiac fibrosis appears to be an early feature of the disease, occurring in many presymptomatic carriers before the onset of overt disease. As with most monogenic cardiomyopathies, no evidence-based treatment is available for presymptomatic carriers.
Aims
The PHOspholamban RElated CArdiomyopathy intervention STudy (iPHORECAST) is designed to demonstrate that pre-emptive treatment of presymptomatic PLN p.Arg14del carriers using eplerenone, a mineralocorticoid receptor antagonist with established antifibrotic effects, can reduce disease progression and postpone the onset of overt disease.
Methods
iPHORECAST has a multicentre, prospective, randomised, open-label, blinded endpoint (PROBE) design. Presymptomatic PLN p.Arg14del carriers are randomised to receive either 50 mg eplerenone once daily or no treatment. The primary endpoint of the study is a multiparametric assessment of disease progression including cardiac magnetic resonance parameters (left and right ventricular volumes, systolic function and fibrosis), electrocardiographic parameters (QRS voltage, ventricular ectopy), signs and/or symptoms related to DCM and ACM, and cardiovascular death. The follow-up duration is set at 3 years.
Baseline results
A total of 84 presymptomatic PLN p.Arg14del carriers (
n
= 42 per group) were included. By design, at baseline, all participants were in New York Heart Association (NHYA) class I and had a left ventricular ejection fraction > 45% and < 2500 ventricular premature contractions during 24-hour Holter monitoring. There were no statistically significant differences between the two groups in any of the baseline characteristics. The study is currently well underway, with the last participants expected to finish in 2021.
Conclusion
iPHORECAST is a multicentre, prospective randomised controlled trial designed to address whether pre-emptive treatment of PLN p.Arg14del carriers with eplerenone can prevent or delay the onset of cardiomyopathy. iPHORECAST has been registered in the clinicaltrials.gov-register (number: NCT01857856).</abstract><cop>Houten</cop><pub>Bohn Stafleu van Loghum</pub><pmid>34143416</pmid><doi>10.1007/s12471-021-01584-5</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1568-5888 |
| ispartof | Netherlands heart journal, 2022-02, Vol.30 (2), p.84-95 |
| issn | 1568-5888 1876-6250 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8799798 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; Springer Nature OA/Free Journals |
| subjects | Cardiac arrhythmia Cardiology Cardiomyocytes Cardiomyopathy Drug dosages Ejection fraction Electrocardiography Ergometry Heart failure Hyperkalemia Medical Education Medical ethics Medicine Medicine & Public Health Original Article – Study Design Article Original – Study Design Outpatient care facilities Potassium Task forces |
| title | Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A34%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rationale%20and%20design%20of%20the%20PHOspholamban%20RElated%20CArdiomyopathy%20intervention%20STudy%20(i-PHORECAST)&rft.jtitle=Netherlands%20heart%20journal&rft.au=te%20Rijdt,%20W.%20P.&rft.date=2022-02-01&rft.volume=30&rft.issue=2&rft.spage=84&rft.epage=95&rft.pages=84-95&rft.issn=1568-5888&rft.eissn=1876-6250&rft_id=info:doi/10.1007/s12471-021-01584-5&rft_dat=%3Cproquest_pubme%3E2729534655%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2729534655&rft_id=info:pmid/34143416&rfr_iscdi=true |